These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9568709)

  • 21. [Endocrine disruptors and nuclear receptors].
    Watanabe H; Iguchi T; Morohashi K
    Nihon Rinsho; 2002 Feb; 60(2):397-403. PubMed ID: 11857933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Activation of transcriptional factor by signal transduction: overview].
    Kato S
    Tanpakushitsu Kakusan Koso; 2000 Jun; 45(9 Suppl):1523-5. PubMed ID: 10879129
    [No Abstract]   [Full Text] [Related]  

  • 23. Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events.
    Blask DE; Sauer LA; Dauchy RT; Holowachuk EW; Ruhoff MS; Kopff HS
    Cancer Res; 1999 Sep; 59(18):4693-701. PubMed ID: 10493527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Classification of environmental endocrine disruptors].
    Arao Y; Kayama F
    Nihon Rinsho; 2000 Dec; 58(12):2376-8. PubMed ID: 11187724
    [No Abstract]   [Full Text] [Related]  

  • 25. Endocrine disruptors targeting ERbeta function.
    Swedenborg E; Pongratz I; Gustafsson JA
    Int J Androl; 2010 Apr; 33(2):288-97. PubMed ID: 20050941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endocrine active agents: implications of adverse and non-adverse changes.
    Foster PM; McIntyre BS
    Toxicol Pathol; 2002; 30(1):59-65. PubMed ID: 11892727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proceedings of the 5th Copenhagen Workshop on Endocrine Disrupters: Ubiquitous endocrine disrupters and possible human health effects, 20-22 May 2009.
    Int J Androl; 2010 Apr; 33(2):251-474. PubMed ID: 20806455
    [No Abstract]   [Full Text] [Related]  

  • 28. The endocrine effects of mercury in humans and wildlife.
    Tan SW; Meiller JC; Mahaffey KR
    Crit Rev Toxicol; 2009; 39(3):228-69. PubMed ID: 19280433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Endocrine disruptors are a novel direction of endocrinologic scientific investigation].
    Iaglova NV; Iaglov VV
    Vestn Ross Akad Med Nauk; 2012; (3):56-61. PubMed ID: 22712276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whither the impending european regulation of presumed endocrine disruptors?
    Autrup HN; Berry SC; Cohen SM; Creppy EE; de Camargo JL; Dekant W; Dietrich D; Galli CL; Goodman JI; Gori GB; Greim HA; Klaunig JE; Lotti M; Marquardt HW; Wallace KB; Yamazaki H
    Regul Toxicol Pharmacol; 2016 Dec; 82():A1-A2. PubMed ID: 27615676
    [No Abstract]   [Full Text] [Related]  

  • 31. How does the melatonin receptor decode a photoperiodic signal in the pars tuberalis?
    Morgan PJ; Messager S; Webster C; Barrett P; Ross A
    Adv Exp Med Biol; 1999; 460():165-74. PubMed ID: 10810511
    [No Abstract]   [Full Text] [Related]  

  • 32. Activation of steroid hormone receptors: Shed light on the in silico evaluation of endocrine disrupting chemicals.
    Chen Q; Tan H; Yu H; Shi W
    Sci Total Environ; 2018 Aug; 631-632():27-39. PubMed ID: 29522903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proceedings of the 5th Copenhagen Workshop on endocrine disrupters: ubiquitous endocrine disrupters and possible human health effects. Preface.
    Andersson AM; Bay K; Grigor KM; Toppari J; Skakkebaek NE
    Int J Androl; 2010 Apr; 33(2):251. PubMed ID: 20487041
    [No Abstract]   [Full Text] [Related]  

  • 34. [Cell and disease. IX. Receptor pathology].
    Drexhage HA; Brinkmann AO; Maassen JA
    Ned Tijdschr Geneeskd; 1993 Oct; 137(44):2243-9. PubMed ID: 8255319
    [No Abstract]   [Full Text] [Related]  

  • 35. Assessment of endocrine disruptors: approaches, issues, and uncertainties.
    Chen CW
    Folia Histochem Cytobiol; 2001; 39 Suppl 2():20-3. PubMed ID: 11820607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melatonin receptor signaling: finding the path through the dark.
    Masana MI; Dubocovich ML
    Sci STKE; 2001 Nov; 2001(107):pe39. PubMed ID: 11698691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of endocrine disruptors in ocular surface diseases.
    Pontelli RCN; Souza MCO; Fantucci MZ; de Andrade M; Rocha EM
    Med Hypotheses; 2019 Jan; 122():157-164. PubMed ID: 30593402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of the human Mel 1a melatonin receptor using anti-receptor antibodies.
    Brydon L; Barrett P; Morgan PJ; Strosberg AD; Jockers R
    Adv Exp Med Biol; 1999; 460():215-20. PubMed ID: 10810516
    [No Abstract]   [Full Text] [Related]  

  • 39. An approach to the development of quantitative models to assess the effects of exposure to environmentally relevant levels of endocrine disruptors on homeostasis in adults.
    Ben-Jonathan N; Cooper RL; Foster P; Hughes CL; Hoyer PB; Klotz D; Kohn M; Lamb DJ; Stancel GM
    Environ Health Perspect; 1999 Aug; 107 Suppl 4(Suppl 4):605-11. PubMed ID: 10421770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting chemical impacts on vertebrate endocrine systems.
    Nichols JW; Breen M; Denver RJ; Distefano JJ; Edwards JS; Hoke RA; Volz DC; Zhang X
    Environ Toxicol Chem; 2011 Jan; 30(1):39-51. PubMed ID: 20963851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.